Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.58 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.58 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.58 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040685 | 1.00 | TXNRD1 (0.58) | TXNRD1TXNRD3TXNRD2BAZ1ACYP3A4 | |
| Biphenyl SCHEMBL27839338 | 0.89 | NPBWR1 (0.54) | TXNRD1TXNRD3TXNRD2BAZ1AALDH1A1 | |
| SCHEMBL16420047 | 0.87 | TXNRD1 (0.50) | TXNRD1TXNRD3TXNRD2BAZ1ACYP3A4 | |
| SCHEMBL28382100 | 0.87 | NPBWR1 (0.55) | BAZ1AALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL28385301 | 0.83 | BAZ1A (0.49) | TXNRD1TXNRD3TXNRD2BAZ1ACYP3A4 | |
| SCHEMBL537862 | 0.78 | PARP1 (0.53) | TXNRD1TXNRD3TXNRD2CYP3A4NAMPT | |
| SCHEMBL1012937 | 0.77 | BAZ1A (0.60) | TXNRD1TXNRD3TXNRD2BAZ1AALDH1A1 | |
| SCHEMBL4515288 | 0.77 | ALDH1A1 (0.62) | BAZ1AALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL366012 | 0.77 | ALDH1A1 (0.62) | TXNRD1TXNRD3TXNRD2BAZ1ACYP3A4 | |
| SCHEMBL30626616 | 0.77 | BAZ1A (0.60) | TXNRD1TXNRD3TXNRD2BAZ1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873407-B1 | TWO-COMPONENT SYSTEM FOR ARTIFICIAL HAIR DYEING | HENKEL AG & CO KGAA (DE) | 2025-04-09 | — | — | EP | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| CN-101318939-A | Method for preparing medicament midbody 5-bromine-6-amido quinoxaline | JIAXING INST OF APPLIED CHEMIS (CN) | 2008-12-10 | — | — | CN | claimed |
| WO-2025137303-A1 | META-PHENYLENEDIAMINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF | FLEXSYS AMERICA L.P. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| WO-2025067509-A1 | EGFR DEGRADANT, AND PREPARATION METHOD AND USE THEREFOR | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-12077527-B2 | Compositions and methods for inhibiting ACSS2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117203199-A | N2-phenylpyrimidine-2, 4-diamine compounds, methods of making and using the same | 毕利吉生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2000038684-A1 | (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES FOR THE TREATMENT OF PAIN | ALLERGAN SALES, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1041930-C | [1,2,4]triazolo[4,3-a] quinoxaline derivatives, their preparation and use | NOVO NORDISK AS (DK) | 1999-02-03 | — | — | CN | disclosed |
| CN-1122601-A | [1, 2, 4] triazolo [4, 3-a ] quinoxaline derivatives, their preparation and use | NOVO NORDISK AS (DK) | 1996-05-15 | — | — | CN | disclosed |
| EP-0353531-B1 | HAIR DYE | Henkel Kommanditgesellschaft auf Aktien (DE) | 1993-04-21 | — | — | EP | disclosed |
| US-5089025-A | HAIR DYE COMPOSITIONS AND CERTAIN 1,2,3,4-TETRAHYDRONITROQUINOXALINES USEFUL THEREIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-02-18 | — | — | US | disclosed |
| EP-0426719-A1 | A HAIR DYE | Henkel Kommanditgesellschaft auf Aktien (DE) | 1991-05-15 | — | — | EP | disclosed |
| WO-1990001050-A1 | A HAIR DYE | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-02-08 | — | — | WO | disclosed |
| EP-0353531-A1 | Hair dye | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077527-B2 | Compositions and methods for inhibiting ACSS2 | ACSS2, ACSL3, ACSL1 | TXNRD1 902/4885TXNRD3 514/4885TXNRD2 300/4885 |
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | TXNRD1 4350/4885TXNRD3 4587/4885TXNRD2 3603/4885 |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | EGFR, ERBB2, ERBB4 | TXNRD1 1617/4885TXNRD3 2224/4885TXNRD2 2859/4885 |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | TXNRD1 1404/4885TXNRD3 2275/4885TXNRD2 2244/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | TXNRD1 4438/4885TXNRD3 4616/4885TXNRD2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.